Coburn BW, et al. - Herein the experts sought to determine if allopurinol dose escalation was related to cause-specific mortality in patients with gout. This study was the largest of allopurinol's impact on mortality and the first to use a rigorous active-comparator design. Findings suggested that dose escalation was related to a small (<10%) increase in all-cause mortality, thereby, suggesting unlikeliness of allopurinol to improve survival as currently prescribed in real life practice characterized by limited dose elevation.